Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT07059286
Enrolling by invitation Observational

Maternal Risk, Fetal-Neonatal Brain Connectivity, and Early Neurodevelopment: A Longitudinal Observational Study

NCT07059286 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2025-07
Last updated
2025-07-10

Condition(s) studied

PregnancyNeurodevelopmentBrain ConnectivityNeurodevelopment Outcome

Investigational drug(s) / intervention(s)

Maternal Frailty Inventory (MaFra) QuestionnaireFetal Resting-State Functional MRIMaternal Emotional ReactivityNeonatal Resting-State Functional MRILongitudinal Neurodevelopmental Testing Battery

Maternal Frailty Inventory (MaFra) Questionnaire: A validated psychometric inventory designed to assess maternal clinical, psychological, and lifestyle risk factors during pregnancy. The composite risk score is used to stratify participants into low- or medium/high-risk categories. Administered during pregnancy, the inventory informs classification and predictive modeling of fetal and child neurodevelopmental outcomes.

Fetal Resting-State Functional MRI: Non-invasive resting-state functional MRI scans performed during gestation (fetal) life to assess functional connectivity across sensorimotor, auditory, visual, language, and attention networks. Imaging data are analyzed to derive local and global connectivity measures and indices of segregation and integration among functional brain systems. Structural MRI is used to confirm normal brain morphology.

Maternal Emotional Reactivity: During fetal rs-fMRI acquisition, mothers listen to emotionally evocative musical excerpts while rating their emotional responses. These self-reported ratings (valence and arousal) are later correlated with fetal brain connectivity responses.

Neonatal Resting-State Functional MRI: Non-invasive MRI scanning protocol conducted during the neonatal period to acquire resting-state functional MRI (rs-fMRI) data. The scan is performed while the newborn is in a natural sleep state, using motion-optimized sequences to assess functional connectivity between brain regions. The focus is on sensorimotor, auditory, visual, language, and attention networks. Structural MRI is also acquired to verify normative brain morphology. Imaging outcomes are used in longitudinal analyses to link early brain connectivity with cognitive and behavioral development.

Longitudinal Neurodevelopmental Testing Battery: Standardized neuropsychological and behavioral assessments are administered at multiple timepoints between birth and 72 months of age. Domains evaluated include sensorimotor skills, cognitive abilities, language development, executive function, social-emotional regulation, and adaptive behaviors. Data are used to compute specific and composite scores that reflect neurocognitive and behavioral profiles. These are later integrated with prenatal and neonatal brain imaging and maternal risk data to model individual neurodevelopmental trajectories.

Study summary

This study aims to understand how a pregnant woman's health, lifestyle, and psychological state-especially when associated with known risk factors-might influence the developing brain of her baby, both before and after birth. Specifically, the research investigates whether differences in brain connectivity observed through fetal and neonatal magnetic resonance imaging (MRI) can predict how a child will develop cognitively, emotionally, and behaviorally from birth through early childhood.

This is a prospective, observational study that will follow 160 pregnant women and their children over time. Participants will be enrolled at the Gynecology and Obstetrics Unit of San Raffaele Hospital in Milan. Using advanced brain imaging techniques (resting-state functional MRI), the study will examine how key brain systems-such as those involved in movement, hearing, vision, language, and attention-are connected during fetal life and shortly after birth. The study also evaluates how these patterns of brain connectivity relate to later developmental outcomes, assessed through standard neuropsychological tests from birth up to 6 years of age.

One of the study's core hypotheses is that early patterns of brain connectivity-especially when combined with detailed profiles of maternal health and risk-can serve as early markers of a child's neurodevelopmental path. To explore this, the study uses an integrated approach that combines imaging data with clinical and psychological information from the mother (e.g., her stress levels, medical history, and lifestyle habits).

Participants are grouped based on the "Maternal Frailty Inventory," a tool that captures the cumulative risk profile of each mother. The sample will include mothers with both low and medium-high risk scores. This grouping allows researchers to investigate how varying degrees of maternal risk are reflected in the baby's early brain organization and how this, in turn, influences developmental milestones.

A secondary aim of the study is to investigate how emotional responses to music may affect fetal brain activity. During the fetal MRI, mothers will listen to selected musical pieces. Researchers will examine if the baby's brain is influenced by the mother's emotional state.

Ultimately, the study hopes to build predictive models-using artificial intelligence and advanced statistical techniques-that can estimate a child's developmental trajectory based on early brain imaging and maternal data. This could provide an important step toward early identification of children who might benefit from developmental support or intervention, even before symptoms appear.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Pregnant women (biologically female) receiving care at the Gynecology and Obstetrics Unit, San Raffaele Hospital, Milan. * Age ≥ 18 years at time of enrollment. * Singleton pregnancy. * Gestational age within the range suitable for fetal MRI acquisition (typically 24-35 weeks gestation). * Willing and able to provide written informed consent. * Willing to undergo fetal and/or neonatal resting-state fMRI as part of the observational study protocol. * Willing to complete maternal questionnaires assessing clinical, lifestyle, and emotional factors (e.g., MaFra Inventory, anxiety scales). * Willing to participate in postnatal follow-up assessments of the child, including neurodevelopmental evaluations from birth to 72 months. * Fetuses with normal brain morphology confirmed by structural MRI. * Fetuses and neonates without signal alterations on structural MRI. Exclusion Criteria: * Twin or multiple gestation pregnancies. * Fetal diagnosis of any major structural or genetic anomaly known to impact neurodevelopment. * Evidence of fetal brain parenchymal signal alterations or neurodevelopmental abnormalities as assessed by structural MRI and confirmed by an experienced neuroradiologist. * Maternal contraindications to undergoing MRI (e.g., presence of non-MRI-compatible implants or severe claustrophobia).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Neuroradiology Unit and CERMAC, IRCCS Ospedale San Raffaele Milan MI

More IRCCS San Raffaele trials in Italy

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07059286 on ClinicalTrials.gov ↗ ← All trials in Italy